Molecular Medicine Research Institute (MMRI)

mmrx.org

The Molecular Medicine Research Institute (MMRI) is committed to translating scientific laboratory findings into direct patient care. Since 1995, MMRI has been exploring the molecular basis of chronic diseases and bridging the gap between science and medical practice through a unique two-part niche program.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industry Outlook

SANGAMO THERAPEUTICS AND CHROMA MEDICINE ANNOUNCE OPTION AND LICENSE AGREEMENT TO EVALUATE AND DEVELOP ZINC FINGER PROTEINS FOR EPIGENETIC EDITING

Businesswire | July 21, 2023

news image

Sangamo Therapeutics, Inc. a clinical-stage genomic medicine company and Chroma Medicine, Inc. a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced they have entered into a research evaluation, option and license agreement to develop epigenetic medicines leveraging zinc finger proteins (ZFPs) for sequence-specific DNA recognition. Over the course of two decades, Sangamo has built and validated the world’s largest library of ZFPs, deployin...

Read More

Research

ASIA'S FIRST INDUSTRIAL INSECT COMPANY, NUTRITION TECHNOLOGIES, CLOSES US$20M EQUITY ROUND TO LAUNCH NEW PRODUCTS AND EXPAND INTO NEW MARKETS

Nutrition Technologies | September 19, 2022

news image

On 19th September 2022 Nutrition Technologies completed an equity venture round of US$ 20m. The round was led by PTT Ventures and supported by Sumitomo Corporation, ING Sustainable Investments, Mandala Capital, as well as continued participation from existing investors: Openspace Ventures, SEEDs Capital and Hera Capital. The round was advised by ING Corporate Finance. The proceeds will be used to fund an expansion into new markets; launch new products; accelerate R&D; and create new strategi...

Read More

MedTech

EVAXION BIOTECH IDENTIFIES GONORRHEA AS SECOND BACTERIAL PRODUCT TARGET

Evaxion Biotech | July 04, 2022

news image

The clinical-stage biotechnology company Evaxion Biotech A/S which specializes in the creation of AI-driven immunotherapies, said today that it has chosen gonorrhea as its second bacterial target for the Company's EVX-B2 vaccine product candidate. Evaxion has opted to create a preventative vaccination against Gonorrhea, a sexually transmitted disease (STD) that has fast acquired antibiotic resistance, as its second bacterial target. Based on preliminary results in pre-clinical...

Read More

LYGENESIS ANNOUNCES FOUR PEER-REVIEWED PAPERS ARE PUBLISHED ON ITS ORGAN REGENERATION TECHNOLOGY

LyGenesis | August 28, 2020

news image

LyGenesis, Inc., a biotechnology company focused on regenerative medicine, announced today that four peer-reviewed papers have been published on its organ regeneration technology. LyGenesis' lead development asset is liver regeneration, which was the focus of the first two papers. Development of Ectopic Livers by Hepatocyte Transplantation into Swine Lymph Nodes by Fontes et al. was published this month in Liver Transplantation, demonstrating that functional mini-livers could be grown using ...

Read More
news image

Industry Outlook

SANGAMO THERAPEUTICS AND CHROMA MEDICINE ANNOUNCE OPTION AND LICENSE AGREEMENT TO EVALUATE AND DEVELOP ZINC FINGER PROTEINS FOR EPIGENETIC EDITING

Businesswire | July 21, 2023

Sangamo Therapeutics, Inc. a clinical-stage genomic medicine company and Chroma Medicine, Inc. a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced they have entered into a research evaluation, option and license agreement to develop epigenetic medicines leveraging zinc finger proteins (ZFPs) for sequence-specific DNA recognition. Over the course of two decades, Sangamo has built and validated the world’s largest library of ZFPs, deployin...

Read More
news image

Research

ASIA'S FIRST INDUSTRIAL INSECT COMPANY, NUTRITION TECHNOLOGIES, CLOSES US$20M EQUITY ROUND TO LAUNCH NEW PRODUCTS AND EXPAND INTO NEW MARKETS

Nutrition Technologies | September 19, 2022

On 19th September 2022 Nutrition Technologies completed an equity venture round of US$ 20m. The round was led by PTT Ventures and supported by Sumitomo Corporation, ING Sustainable Investments, Mandala Capital, as well as continued participation from existing investors: Openspace Ventures, SEEDs Capital and Hera Capital. The round was advised by ING Corporate Finance. The proceeds will be used to fund an expansion into new markets; launch new products; accelerate R&D; and create new strategi...

Read More
news image

MedTech

EVAXION BIOTECH IDENTIFIES GONORRHEA AS SECOND BACTERIAL PRODUCT TARGET

Evaxion Biotech | July 04, 2022

The clinical-stage biotechnology company Evaxion Biotech A/S which specializes in the creation of AI-driven immunotherapies, said today that it has chosen gonorrhea as its second bacterial target for the Company's EVX-B2 vaccine product candidate. Evaxion has opted to create a preventative vaccination against Gonorrhea, a sexually transmitted disease (STD) that has fast acquired antibiotic resistance, as its second bacterial target. Based on preliminary results in pre-clinical...

Read More
news image

LYGENESIS ANNOUNCES FOUR PEER-REVIEWED PAPERS ARE PUBLISHED ON ITS ORGAN REGENERATION TECHNOLOGY

LyGenesis | August 28, 2020

LyGenesis, Inc., a biotechnology company focused on regenerative medicine, announced today that four peer-reviewed papers have been published on its organ regeneration technology. LyGenesis' lead development asset is liver regeneration, which was the focus of the first two papers. Development of Ectopic Livers by Hepatocyte Transplantation into Swine Lymph Nodes by Fontes et al. was published this month in Liver Transplantation, demonstrating that functional mini-livers could be grown using ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us